Loading...
Loading...
Reprogramming aging at the genetic level. Turning back the epigenetic clock.
Aging is increasingly viewed as a programmable process. Certain genes (Klotho, TERT, FOXO3) are associated with exceptional longevity. Gene therapy could activate these protective pathways permanently, effectively slowing or reversing biological decay.
| Gene / Pathway | Function | Therapy Status | Potential Effect |
|---|---|---|---|
| Telomerase (TERT) | Extends telomeres | Animal trials / Self-experiment | 24% lifespan extension (mice) |
| Klotho | Anti-aging hormone | Early research | Cognitive & CV protection |
| FOXO3 | Stress resistance | Preclinical | Associated with Centenarians |
| Yamanaka Factors | Cellular reprogramming | Active (Altos Labs) | Epigenetic age reversal |
| Sirtuin Activators | Metabolic regulation | Molecules available | Healthspan extension |
The most exciting development in longevity. Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) can reprogram adult cells back to a stem-like state. Partial reprogramming—using these factors briefly—can reverse epigenetic age without losing cell identity.
More approved gene therapies for orphan diseases. Refinement of delivery systems (AAV/LNP).
First longevity-focused gene therapies (TERT, Klotho) enter early human safety trials.
Anti-aging gene therapies become elective options in optimization centers.
Note: Medical tourism centers in unregulated jurisdictions may offer earlier, high-risk access to these technologies.